Autosomal Alport syndrome is a hereditary disease of the basement membranes caused by variants in COL4A3 or COL4A4. Biallelic variants produce the generally severe autosomal recessive form, while a heterozygous variant can cause a more variable autosomal dominant form. The alteration of type IV collagen weakens the glomerular basement membrane and leads to hematuria, proteinuria, and progressive loss of kidney function.
Autosomal dominant and autosomal recessive Alport syndrome
The COL4A3 and COL4A4 genes encode the alpha-3 and alpha-4 chains of type IV collagen. Together with the alpha-5 chain, they form an essential structural network of the glomerular basement membrane and specialized membranes of the cochlea and the eye. This network provides mechanical strength and maintains the integrity of the renal filtration barrier.
Pathogenic variants alter collagen synthesis, assembly, or stability and lead to thinning, irregular thickening, and lamination of the glomerular basement membrane. In the recessive form, both copies of one of the genes are affected, and progression is usually rapid. In the dominant form, a single altered copy causes a spectrum ranging from isolated hematuria to chronic kidney disease. Its specific prevalence is not well established, partly due to underdiagnosis of mild dominant phenotypes.
Symptoms
The earliest manifestation is usually persistent microscopic hematuria, present from infancy in the recessive form and variable in onset in the dominant form. In the recessive form, proteinuria, hypertension, and progressive renal deterioration appear during childhood or adolescence; without treatment, many individuals reach end-stage renal disease before age 30. Progressive sensorineural hearing loss, anterior lenticonus, and retinal abnormalities may also occur. The dominant form usually progresses slowly, although some patients develop proteinuria and renal disease in adulthood; auditory and ocular involvement is infrequent.
Disease management
There is no curative treatment that restores the normal network of type IV collagen. Management includes nephrological follow-up, blood pressure control, measurement of albuminuria or proteinuria, and assessment of renal function. Early blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists may delay progression. In adults with proteinuria and chronic kidney disease, SGLT2 inhibitors may be considered depending on the clinical context. It is also recommended to avoid nephrotoxins, monitor hearing and vision, study at-risk family members, and offer genetic counseling. Dialysis and kidney transplantation are used in end-stage disease.
Genes analyzed
Bibliography
Nozu K, Yamamura T, Horinouchi T. Alport Syndrome. GeneReviews®. 2025 update.
Torra R, Lipska-Zietkiewicz B, Acke F, et al. Diagnosis, management and treatment of Alport syndrome: 2024 guideline on behalf of ERKNet, ERA and ESPN. Nephrol Dial Transplant. 2025;40(6):1091-1106.
Savige J, Lipska-Zietkiewicz BS, Watson E, et al. Guidelines for Genetic Testing and Management of Alport Syndrome. Clin J Am Soc Nephrol. 2022;17(1):143-154.
Savige J, Huang M, Croos Dabrera MS, et al. Genotype-Phenotype Correlations for Pathogenic COL4A3-COL4A5 Variants in X-Linked, Autosomal Recessive, and Autosomal Dominant Alport Syndrome. Front Med. 2022;9:865034.
